Extramedullary acute promyelocytic leukemia
BACKGROUND Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all‐trans retinoic acid (ATRA) than after any other treatment. METHODS The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult w...
Gespeichert in:
| Veröffentlicht in: | Cancer 1996-12, Vol.78 (12), p.2510-2514 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2514 |
|---|---|
| container_issue | 12 |
| container_start_page | 2510 |
| container_title | Cancer |
| container_volume | 78 |
| creator | Wiernik, Peter H. De Bellis, Roberto Muxi, Pablo Dutcher, Janice P. |
| description | BACKGROUND
Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all‐trans retinoic acid (ATRA) than after any other treatment.
METHODS
The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult whose initial treatment was chemotherapy are presented, and the literature on extramedullary relapse of APL is reviewed.
RESULTS
Twenty‐six patients were identified, including the 2 current patients. Ethnicity could be determined in 23 patients, 17 of whom were of other than Northern European extraction. The most common sites of extramedullary disease were the skin (15 patients), central nervous system (5 patients), mediastinum (3 patients), and, curiously, gingiva (3 patients). Extramedullary leukemia developed in 19 patients: after treatment with ATRA (6 patients), cytotoxic chemotherapy (12 patients), or both (1 patient), and developed in 7 others before any treatment for leukemia was given.
CONCLUSIONS
These data suggest but do not prove that extramedullary APL may occur more frequently after ATRA than other therapy, since ATRA has been available for a relatively short period of time. However, it is clear from the literature that extramedullary APL may occur after chemotherapy or before any treatment. Cancer 1996; 78:2510‐4. |
| doi_str_mv | 10.1002/(SICI)1097-0142(19961215)78:12<2510::AID-CNCR10>3.0.CO;2-Z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78604457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78604457</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4850-9bba9e3c7cd542c1e060339067d3de0ab892fb410131c068edc22dd66c9ed0693</originalsourceid><addsrcrecordid>eNqNkNFq2zAUhsXYaNN0j1DIRRkpxek5kmVbaSmkbtcGygLbCiUUDrKsgFc7aa2YNW9fmXi52S52JaTz6-c7H2NXCCME4GfDH9N0eoKg4gAw5ENUKkKO8iROxsgvuEQYjyfT6yD9ln5HuBQjGKWzcx7MP7De7ttH1gOAJJCheNxnB8798teYS7HH9hIluZSqx05v3ta1rmzelKWuNwNtmrUdvNSramPLldmsCzMobfNsq0Ifsk8LXTr7uTv77OHrzc_0Lrif3U7TyX1gwkRCoLJMKytMbHIZcoMWIhBCQRTnIregs0TxRRYioEADUWJzw3meR5FRNodIiT77su31GK-NdWuqCmesB1zaVeMoTiIIQxn74HwbNPXKudou6KUuKr8GIVBrkqg1Sa0SapXQH5O-g5BTa5LIm6StSRIElM6I09yXH3UUTeb97Ko7dX5-3M21M7pc1HppCreLtdVKoo89bWO_i9Ju_gL8D75_4nUv4h30Q5wk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78604457</pqid></control><display><type>article</type><title>Extramedullary acute promyelocytic leukemia</title><source>MEDLINE</source><source>Wiley Journals</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Wiernik, Peter H. ; De Bellis, Roberto ; Muxi, Pablo ; Dutcher, Janice P.</creator><creatorcontrib>Wiernik, Peter H. ; De Bellis, Roberto ; Muxi, Pablo ; Dutcher, Janice P.</creatorcontrib><description>BACKGROUND
Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all‐trans retinoic acid (ATRA) than after any other treatment.
METHODS
The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult whose initial treatment was chemotherapy are presented, and the literature on extramedullary relapse of APL is reviewed.
RESULTS
Twenty‐six patients were identified, including the 2 current patients. Ethnicity could be determined in 23 patients, 17 of whom were of other than Northern European extraction. The most common sites of extramedullary disease were the skin (15 patients), central nervous system (5 patients), mediastinum (3 patients), and, curiously, gingiva (3 patients). Extramedullary leukemia developed in 19 patients: after treatment with ATRA (6 patients), cytotoxic chemotherapy (12 patients), or both (1 patient), and developed in 7 others before any treatment for leukemia was given.
CONCLUSIONS
These data suggest but do not prove that extramedullary APL may occur more frequently after ATRA than other therapy, since ATRA has been available for a relatively short period of time. However, it is clear from the literature that extramedullary APL may occur after chemotherapy or before any treatment. Cancer 1996; 78:2510‐4.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19961215)78:12<2510::AID-CNCR10>3.0.CO;2-Z</identifier><identifier>PMID: 8952559</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>acute leukemia ; Adult ; all‐trans retinoic acid ; Biological and medical sciences ; Child, Preschool ; Elbow - pathology ; extramedullary leukemia ; Fatal Outcome ; Female ; Gingiva - pathology ; Hematologic and hematopoietic diseases ; Humans ; Leukemia, Promyelocytic, Acute - drug therapy ; Leukemia, Promyelocytic, Acute - pathology ; Leukemia, Promyelocytic, Acute - radiotherapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Leukemic Infiltration - drug therapy ; Leukemic Infiltration - pathology ; Leukemic Infiltration - radiotherapy ; Medical sciences ; promyelocytic leukemia</subject><ispartof>Cancer, 1996-12, Vol.78 (12), p.2510-2514</ispartof><rights>Copyright © 1996 American Cancer Society</rights><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4850-9bba9e3c7cd542c1e060339067d3de0ab892fb410131c068edc22dd66c9ed0693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819961215%2978%3A12%3C2510%3A%3AAID-CNCR10%3E3.0.CO%3B2-Z$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819961215%2978%3A12%3C2510%3A%3AAID-CNCR10%3E3.0.CO%3B2-Z$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2510951$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8952559$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wiernik, Peter H.</creatorcontrib><creatorcontrib>De Bellis, Roberto</creatorcontrib><creatorcontrib>Muxi, Pablo</creatorcontrib><creatorcontrib>Dutcher, Janice P.</creatorcontrib><title>Extramedullary acute promyelocytic leukemia</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all‐trans retinoic acid (ATRA) than after any other treatment.
METHODS
The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult whose initial treatment was chemotherapy are presented, and the literature on extramedullary relapse of APL is reviewed.
RESULTS
Twenty‐six patients were identified, including the 2 current patients. Ethnicity could be determined in 23 patients, 17 of whom were of other than Northern European extraction. The most common sites of extramedullary disease were the skin (15 patients), central nervous system (5 patients), mediastinum (3 patients), and, curiously, gingiva (3 patients). Extramedullary leukemia developed in 19 patients: after treatment with ATRA (6 patients), cytotoxic chemotherapy (12 patients), or both (1 patient), and developed in 7 others before any treatment for leukemia was given.
CONCLUSIONS
These data suggest but do not prove that extramedullary APL may occur more frequently after ATRA than other therapy, since ATRA has been available for a relatively short period of time. However, it is clear from the literature that extramedullary APL may occur after chemotherapy or before any treatment. Cancer 1996; 78:2510‐4.</description><subject>acute leukemia</subject><subject>Adult</subject><subject>all‐trans retinoic acid</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Elbow - pathology</subject><subject>extramedullary leukemia</subject><subject>Fatal Outcome</subject><subject>Female</subject><subject>Gingiva - pathology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Humans</subject><subject>Leukemia, Promyelocytic, Acute - drug therapy</subject><subject>Leukemia, Promyelocytic, Acute - pathology</subject><subject>Leukemia, Promyelocytic, Acute - radiotherapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Leukemic Infiltration - drug therapy</subject><subject>Leukemic Infiltration - pathology</subject><subject>Leukemic Infiltration - radiotherapy</subject><subject>Medical sciences</subject><subject>promyelocytic leukemia</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkNFq2zAUhsXYaNN0j1DIRRkpxek5kmVbaSmkbtcGygLbCiUUDrKsgFc7aa2YNW9fmXi52S52JaTz6-c7H2NXCCME4GfDH9N0eoKg4gAw5ENUKkKO8iROxsgvuEQYjyfT6yD9ln5HuBQjGKWzcx7MP7De7ttH1gOAJJCheNxnB8798teYS7HH9hIluZSqx05v3ta1rmzelKWuNwNtmrUdvNSramPLldmsCzMobfNsq0Ifsk8LXTr7uTv77OHrzc_0Lrif3U7TyX1gwkRCoLJMKytMbHIZcoMWIhBCQRTnIregs0TxRRYioEADUWJzw3meR5FRNodIiT77su31GK-NdWuqCmesB1zaVeMoTiIIQxn74HwbNPXKudou6KUuKr8GIVBrkqg1Sa0SapXQH5O-g5BTa5LIm6StSRIElM6I09yXH3UUTeb97Ko7dX5-3M21M7pc1HppCreLtdVKoo89bWO_i9Ju_gL8D75_4nUv4h30Q5wk</recordid><startdate>19961215</startdate><enddate>19961215</enddate><creator>Wiernik, Peter H.</creator><creator>De Bellis, Roberto</creator><creator>Muxi, Pablo</creator><creator>Dutcher, Janice P.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19961215</creationdate><title>Extramedullary acute promyelocytic leukemia</title><author>Wiernik, Peter H. ; De Bellis, Roberto ; Muxi, Pablo ; Dutcher, Janice P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4850-9bba9e3c7cd542c1e060339067d3de0ab892fb410131c068edc22dd66c9ed0693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>acute leukemia</topic><topic>Adult</topic><topic>all‐trans retinoic acid</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Elbow - pathology</topic><topic>extramedullary leukemia</topic><topic>Fatal Outcome</topic><topic>Female</topic><topic>Gingiva - pathology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Humans</topic><topic>Leukemia, Promyelocytic, Acute - drug therapy</topic><topic>Leukemia, Promyelocytic, Acute - pathology</topic><topic>Leukemia, Promyelocytic, Acute - radiotherapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Leukemic Infiltration - drug therapy</topic><topic>Leukemic Infiltration - pathology</topic><topic>Leukemic Infiltration - radiotherapy</topic><topic>Medical sciences</topic><topic>promyelocytic leukemia</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wiernik, Peter H.</creatorcontrib><creatorcontrib>De Bellis, Roberto</creatorcontrib><creatorcontrib>Muxi, Pablo</creatorcontrib><creatorcontrib>Dutcher, Janice P.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wiernik, Peter H.</au><au>De Bellis, Roberto</au><au>Muxi, Pablo</au><au>Dutcher, Janice P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Extramedullary acute promyelocytic leukemia</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1996-12-15</date><risdate>1996</risdate><volume>78</volume><issue>12</issue><spage>2510</spage><epage>2514</epage><pages>2510-2514</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Extramedullary acute promyelocytic leukemia (APL) is rare, and said to be more common after treatment with all‐trans retinoic acid (ATRA) than after any other treatment.
METHODS
The case of a child with extramedullary relapse of APL after initial treatment with ATRA and that of an adult whose initial treatment was chemotherapy are presented, and the literature on extramedullary relapse of APL is reviewed.
RESULTS
Twenty‐six patients were identified, including the 2 current patients. Ethnicity could be determined in 23 patients, 17 of whom were of other than Northern European extraction. The most common sites of extramedullary disease were the skin (15 patients), central nervous system (5 patients), mediastinum (3 patients), and, curiously, gingiva (3 patients). Extramedullary leukemia developed in 19 patients: after treatment with ATRA (6 patients), cytotoxic chemotherapy (12 patients), or both (1 patient), and developed in 7 others before any treatment for leukemia was given.
CONCLUSIONS
These data suggest but do not prove that extramedullary APL may occur more frequently after ATRA than other therapy, since ATRA has been available for a relatively short period of time. However, it is clear from the literature that extramedullary APL may occur after chemotherapy or before any treatment. Cancer 1996; 78:2510‐4.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>8952559</pmid><doi>10.1002/(SICI)1097-0142(19961215)78:12<2510::AID-CNCR10>3.0.CO;2-Z</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 1996-12, Vol.78 (12), p.2510-2514 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78604457 |
| source | MEDLINE; Wiley Journals; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
| subjects | acute leukemia Adult all‐trans retinoic acid Biological and medical sciences Child, Preschool Elbow - pathology extramedullary leukemia Fatal Outcome Female Gingiva - pathology Hematologic and hematopoietic diseases Humans Leukemia, Promyelocytic, Acute - drug therapy Leukemia, Promyelocytic, Acute - pathology Leukemia, Promyelocytic, Acute - radiotherapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukemic Infiltration - drug therapy Leukemic Infiltration - pathology Leukemic Infiltration - radiotherapy Medical sciences promyelocytic leukemia |
| title | Extramedullary acute promyelocytic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A12%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Extramedullary%20acute%20promyelocytic%20leukemia&rft.jtitle=Cancer&rft.au=Wiernik,%20Peter%20H.&rft.date=1996-12-15&rft.volume=78&rft.issue=12&rft.spage=2510&rft.epage=2514&rft.pages=2510-2514&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19961215)78:12%3C2510::AID-CNCR10%3E3.0.CO;2-Z&rft_dat=%3Cproquest_cross%3E78604457%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78604457&rft_id=info:pmid/8952559&rfr_iscdi=true |